The global Nucleic Acid Isolation and Purification Market was valued at USD 902.9 million in 2020 and is projected to reach USD 1,174.1 million by 2025. From 2025 to 2035, the market is forecast to expand at a robust CAGR of 5.2%, ultimately surpassing USD 1,949.3 million by 2035. Growth is being driven by the essential role of nucleic acid purification in molecular diagnostics, genomics research, and the development of personalized medicine.
The increasing adoption of next-generation sequencing (NGS), rapid expansion of infectious disease surveillance programs, and the ongoing evolution of CRISPR-based gene editing platforms are intensifying demand for high-quality nucleic acid extraction solutions. Research efforts centered on cancer biomarkers, liquid biopsies, and transcriptomic profiling have further elevated the need for robust, contamination-free isolation kits.
Additionally, improvements in sample preparation automation-particularly magnetic bead-based and column-free extraction systems-have streamlined workflows and enhanced reproducibility. Strategic investments from both life sciences companies and public-sector precision medicine initiatives are accelerating innovation, while the demand for scalable, automation-compatible purification platforms continues to grow among clinical laboratories and biotechnology firms worldwide
Leading players in the nucleic acid isolation and purification market include Thermo Fisher Scientific, Qiagen N.V., Promega Corporation, and Roche Diagnostics. These companies are actively expanding their molecular biology portfolios through targeted R&D investments, acquisition of platform technologies, and product line extensions.
In 2024, New England Biolabs launched the Monarch Mag Viral DNA/RNA Extraction Kit, aimed at enabling highly sensitive detection of viral pathogens. “Isolating viral nucleic acids is crucial for several areas of life sciences research, including viral genome sequencing, infectious disease detection, and wastewater surveillance,” noted James Deng, Senior Product Marketing Manager at New England Biolabs, Inc.
This product launch is expected to accelerate clinical diagnostics workflows by improving turnaround time, enhancing scalability, and supporting integration with PCR platforms and LIMS. Similarly, Qiagen introduced a dual-phase extraction system combining magnetic bead and membrane-based methods, allowing for simultaneous RNA and DNA purification from a single sample with improved purity and reduced cross-contamination. These innovations reflect the sector’s focus on addressing evolving laboratory needs and improving assay sensitivity across a range of clinical and research applications.
North America dominates the nucleic acid isolation and purification market, owing to significant funding for genomics research, a mature clinical trial landscape, and the widespread availability of advanced molecular diagnostics labs. The USA National Institutes of Health (NIH) continues to prioritize funding for precision oncology, rare disease genomics, and viral surveillance, all of which are fueling sustained demand for automated and high-throughput sample preparation tools.
In addition, vendor consolidation and integration with digital diagnostics platforms are creating a more streamlined and competitive landscape for clinical laboratories. In Europe, market growth is underpinned by the implementation of national genomic testing strategies and the modernization of biobanking infrastructure. Stringent CE-IVD compliance requirements have increased demand for high-quality purification kits that ensure reproducibility, traceability, and regulatory conformity.
The expanding uptake of RNA-based therapeutics and biomarker validation studies, particularly in oncology and virology, is also propelling adoption across public hospitals, academic institutions, and CROs. With translational research and clinical genomics becoming central to national healthcare frameworks, demand for nucleic acid purification technologies is expected to rise steadily across both regions
A comparative analysis of fluctuations in compound annual growth rate (CAGR) for the nucleic acid isolation and purification market between 2024 and 2025 on a six-month basis is shown below.
By this examination, major variations in the performance of these markets are brought to light, and also trends of revenue generation are captured hence offering stakeholders useful ideas on how to carry on with the market’s growth path in any other given year. January through June covers the first part of the year called half1 (H1), while half2 (H2) represents July to December.
The table below compares the compound annual growth rate (CAGR) for the global nucleic acid isolation and purification industry analysis from 2024 to 2025 during the first half of the year. This overview highlights key changes and trends in revenue growth, offering valuable insights into market dynamics.
H1 is January to June, and H2 is July to December. For the first half (H1) of the period between 2024 and 2034, the company is expected to grow at a CAGR of 6.3%, followed by a rate of growth marginally lower at 6.0% in the second half (H2) of the decade between 2024 and 2034.
| Particular | Value CAGR |
|---|---|
| H1 | 6.3% (2024 to 2034) |
| H2 | 6.0% (2024 to 2034) |
| H1 | 5.6% (2025 to 2035) |
| H2 | 5.1% (2025 to 2035) |
For the later period, going from the H1 2025 to the H2 2035 horizon, growth will slow ever so slightly. It will record about 5.6% of compound annual growth rate (CAGR) growth in the half-decade preceding the current timeline and decelerate further in the following five years down to 5.1%. This market is supposed to shed a 70 basis point slide during the initial five years as well as yet another 90 basis point loss over the latter.
In 2025, DNA extraction and purification kits are projected to account for 60.3% of the total market revenue, cementing their position as the leading product segment. This dominance is fueled by the broad applicability of DNA-based assays in molecular diagnostics, pharmacogenomics, oncology research, and agricultural biotechnology.
These kits are preferred due to their ability to deliver high-purity, contaminant-free yields with minimal user intervention-ensuring compatibility with downstream platforms such as qPCR, sequencing, and microarrays. The growth of the segment has been accelerated by the shift toward magnetic bead-based and column-free systems, which allow for automation, high-throughput processing, and reduced error rates.
Academic and clinical laboratories have increasingly adopted these solutions to improve reproducibility, reduce processing time, and accommodate a wider range of sample types and throughput demands. In the wake of the COVID-19 pandemic, demand for pathogen-specific DNA prep solutions surged, prompting further innovation in ready-to-use, pathogen-agnostic kits. As a result, DNA purification systems continue to form the backbone of nucleic acid sample preparation across diagnostic and research sectors..
Academic research institutions are projected to account for 51.0% of the total revenue share in the nucleic acid isolation and purification market by 2025. This leading position is driven by substantial public and private investments in molecular biology, oncology, virology, and precision medicine initiatives.
Universities, national research labs, and academic medical centers have expanded their genomics infrastructure, supported by programs such as the NIH’s All of Us Research Program and the European Union’s Horizon Europe. These institutions require scalable and reliable purification platforms that support a diverse range of biological samples and experimental designs.
Cost-effectiveness and adaptability have been key purchasing considerations, particularly in high-volume teaching and translational research environments. Integration of nucleic acid isolation into academic curricula and skill-building programs has also contributed to the widespread adoption of standardized kits.
Moreover, academic-industry collaborations and participation in clinical trial networks have heightened the need for high-quality DNA/RNA samples that meet stringent data integrity and reproducibility standards. With the increasing role of biobanks, multi-omics studies, and longitudinal cohort research, academic institutes are expected to remain at the forefront of market demand.
Manufacturers' Focus on Introducing New Products Expected to Drive Market Growth
An eminent alert of bringing new products by manufacturers is one of the major driving forces behind the market for nucleic acid isolation and purification.
For instance, manufacturers develop an improved efficiency, speed, and accuracy for new demands in research, clinical diagnosis, and personalized medicine by working on the provision of new kits and solutions. Because of this emergence, automated systems, user-friendly kits, and application-oriented solutions were developed for areas like Oncology, Infectious Disease Testing, and Pharmacogenomics.
Moreover, the trend for developing portable and rapid purification kits is apt for the emergent requirement for point-of-care and home-based testing, which would be more convenient and accessible to the consumers. While this will increase the reach of the market, it also aids in personalized health monitoring and management.
Continuous launching of new differentiated products positions the manufacturers in capturing competitive market shares, fostering continued market expansion. Apart from increasing regulatory clearances, an innovation-led strategy will play a key role in determining the future growth trend of the nucleic acid isolation and purification market.
The Rising Trend towards Point-of-Care and Home-Based Testing is Likely to Increase the Application of Nucleic Acid Isolation and Purification Kits
The point-of-care or at-home testing trend that is expanding the use of nucleic acid isolation and purification test kits is now changing the very genesis of accessibility and convenience in healthcare. These testing methods allow for rapid diagnostics outside the traditional laboratory setting and help address the need for timely, accurate results.
An increase in self-testing kits regarding genetic disorders, infectious diseases, and chronic condition monitoring-for example, COVID-19 or personalized DNA analysis-emphasizes this trend.
The demand in the market is sustained by consumer needs of portable diagnostic solutions that are easy to use and affordable. A crucial step in these tests is nucleic acid purification, which ensures high-purity nucleic acids to allow valid test results. Test kits targeting saliva or blood spot samples are, for example, easy to collect yet provide clinically accurate results.
The decentralization of healthcare, relieving the burden on hospitals, and the need for patients to be independent in the management of their health-these have hastened the integration into day-to-day use. All these promise continued growth, with manufacturers striving to make nucleic acid isolation and purification kits even more reliable, quicker, and cheaper to further promote diagnostic solutions.
Nucleic acid isolation and purification kits are the latest tools to bring new business opportunities in infectious disease management.
An increase in infectious diseases, both viral and bacterial, has resulted in a rising demand for the effective and reliable diagnosis. Since these diseases may be diagnosed easily using nucleic acid isolation and extraction kits like those utilized in PCR and other molecular diagnostic methods, the growth in market demand for the product is anticipated.
These improvements in diagnostic performance, speed, and reliability ensure the quicker identification and treatment of infectious diseases. With increased global health concerns, such as pandemics and newly emerging infections, governments and healthcare institutions are increasing their investments in diagnostic tools, thus opening up a market for nucleic acid isolation and purification kits.
Development of portable, easy-to-use, and low-cost kits creates opportunities for low-resource settings, hence expansion of market reach. Companies can bring about innovation in how these kits are integrated with next-generation technologies like automation and multiplexing to make the process even more efficient.
Furthermore, the collaborations of diagnostic companies, healthcare providers, and research institutions in enhancing disease surveillance and response further expand the market.
Competition from Alternative Methods for Nucleic Acid Isolation and Purification test kits hinders their market growth
Tests involving antigens or antibodies, for instance, are being more favored lately, given the less complex processes, quicker times, and no substantial laboratory equipment or specialized skill requirements associated with nucleic acid-based tests. These can be deployed at the point of care to yield immediate results, which is really important in an emergency or resource-poor setting.
With the advancement in molecular diagnostics and testing technology, new techniques such as CRISPR-based diagnostics and microfluidics have begun to emerge. These provide much better speed, sensitivity, and ease compared to the traditional processes of nucleic acid isolation and purification. As these alternatives become more available and at a lower cost, they pose significant competition in the diagnostic testing market.
Moreover, these alternatives are going to be more attractive for healthcare providers in resource-poor regions due to the low cost and ease of establishment. This again will limit demand for the more complex nucleic acid isolation kits. These factors can hampers the growth of nucleic acid isolation and purification kits.
The global nucleic acid isolation and purification industry recorded a CAGR of 5.6% during the historical period between 2020 and 2024. The growth of the nucleic acid isolation and purification diagnostics industry was positive as it reached a value of USD 2,038.1 million in 2035 from USD 1,178.6 million in 2025.
Isolation and purification of nucleic acid is the process through which DNA or RNA is obtained from biological samples-blood, tissues, or cells-for use in applications such as genetic testing, PCR, and sequencing. It is concerned with the breaking of cell membranes to release the nucleic acids, removing impurities from the nucleic acids, and high-purity preparation for further analyses. Nucleic acid integrity is very crucial to achieving accurate results in research and clinical diagnostics.
Isolation and purification of the nucleic acids have been increasing in recent years, driven by the COVID-19 pandemic. It accelerated the use of molecular diagnostics, as they were utilized for the diagnosis of infections. In addition, home diagnostic kits and mobile health solutions extend accessibility to those technologies beyond conventional laboratories.
Recent developments in nucleic acid isolation and purification products are toward automation on user-friendly platforms that make the process seamless. Innovations in magnetic bead-based extraction techniques and miniaturized kits improve nucleic acid isolation in speed, efficiency, and accuracy. Such technologies have also been made more accessible and user-friendly by the introduction of mobile applications and real-time data analysis tools.
Going forward, nucleic acid isolation and purification find emerging growth in health technologies where it is capable of collecting a biological sample and its real-time analysis.
The complete automation of nucleic acid isolation processes and the use of artificial intelligence will further enhance accuracy and efficiency. With the development of home-based diagnostics such as liquid biopsies and multi-analyte tests, these technologies will continue to form the future of healthcare diagnostics, extending their use even more.
With a contribution of 48.1% to the global market share, Tier 1 firms are designated as the bigger firms. They have large production facilities, heavy investments in research and development, and wide distribution channels, which qualify them as market leaders and innovators.
Their capacity to produce in bulk establishes a market in which they can satisfy the high demand from consumers. Tier 1 has the major players such as Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG and Agilent Technologies Inc.
Tier 2 firms are comparatively smaller when compared to Tier 1 companies. Tier 2 firms capture a market share of 32.5% globally. Tier 2 firms, though being smaller in magnitude when compared to Tier 1, still hold significant importance within the nucleic acid isolation and purification sector.
Tier 2 firms concentrate in niche or nascent markets or offer specialized solutions or products intended for regionalized markets or specific consumer requirements. Their power comes in the form of agility and being able to craft creative solutions for underprivileged or niche market segments. Primary Companies under this group are Illumina, Inc., Danaher Corporation and QIAGEN
The section below covers the industry analysis for the nucleic acid isolation and purification sales for different countries. Market demand analysis on key countries in several regions of the globe, including North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East & Africa is provided.
The United States is anticipated to remain at the forefront in North America, with a CAGR of 2.5% through 2035. In South Asia & Pacific, India is projected to witness the highest CAGR in the market of 4.5% by 2035.
The United States leads the global market with superior share in 2024. The United States is anticipated to reflect a CAGR of 2.5% over the forecast period (2025 to 2035).
Technological developments in biotechnology, particularly in genomics and molecular diagnostics, have been a major factor in the increasing need for efficient and accurate nucleic acid extraction methods.
Boosting DNA and RNA in diverse diagnostic uses-PCR, gene sequencing, and discovery of biomarkers-adds fuel to this demand. Moreover, USA precision medicine is in its frontiers, where accurate genetic analysis is needed in the majority of cases for targeted therapy and individualized treatment. With accelerating advancements in biotech and continued maturation of effective testing solutions, additional growth is anticipated within the USA market for nucleic acid isolation and purification.
In 2024, Germany held a dominant revenue in the Western Europe market and is expected to grow with a CAGR of 3.2%.
Driving factors for nucleic acid isolation and purification technologies in Germany include the established pharmaceutical and biotech industries. Germany is one of the leading countries in pharmaceutical and biotechnology research, with various companies and research institutions committed to furthering molecular diagnostics and genomic medicine.
This strong industry foundation increases the demand for a reliable and efficient method of nucleic acid isolation important in drug development, genetic testing, and personalized medicine. In addition, while this country is paying high attention to precision medicine and molecular biology, there is an urgent need for high-quality nucleic acid extraction technologies.
Besides, Germany's highly developed manufacturing enables the production of innovative isolation and purification kits to meet domestic and international marketplace demands. Besides, the close cooperation between academia, pharmaceuticals, and healthcare providers in innovating and vastly disseminating nucleic acid isolation technologies contributes a lot to the market growth of the country.
India occupies a leading value share in South Asia & Pacific market in 2024 and is expected to grow with a CAGR of 5.4% during the forecasted period.
Among some of the major factors contributing toward the demand for nucleic acid isolation and purification technologies in South Korea are governmental investments in healthcare and biotechnology research. The Government of South Korea has been notably investing in the biotechnology sector through funding, grants, and strategic initiatives to drive improvement in medical research and diagnostics.
The investment of such a kind in molecular biology, genetics, and precision medicine increases the demand for valid ways of nucleic acid isolation. Establishment of infrastructures for biotechnology, specifically those for genomic research and drug development, further develops the country for the demand at the top of the line technologies in nucleic acid extraction.
To the same extent, improvement in diagnostics and prevention of disease, as was emphasized by South Korea, makes way for accelerated use of these technologies. Government commitment to healthcare innovation, along with South Korea's position in global diagnostic supply chains, gives the nucleic acid isolation and purification solutions market significant momentum.
The nucleic acid isolation and purification market is highly competitive, with both established leaders and new players constantly vying for market share. Leading companies focus on offering cutting-edge solutions by collaborating with the established players that combine advanced technology with user-friendly features.
Many of these competitors incorporate smart technology into their products, ensuring seamless integration with mobile apps and cloud-based platforms for real-time data monitoring.
Recent Industry Developments in Nucleic Acid Isolation and Purification Market
In terms of product, the industry is divided into DNA extraction and purification kits and RNA extraction and purification kits
In terms of application, the industry is divided into plasmid isolation and purification, DNA isolation and purification and RNA isolation and purification
In terms of sample, the industry is divided into pharmaceutical companies, biotechnology companies, contract research organizations and academic research institutes
Key countries of North America, Latin America, East Asia, South Asia & Pacific, Western Europe, Eastern Europe, and Middle East and Africa (MEA) have been covered in the report.
The global nucleic acid isolation and purification industry is projected to witness CAGR of 5.2% between 2025 and 2035.
The global nucleic acid isolation and purification industry stood at USD 1,105.3 million in 2024.
The global nucleic acid isolation and purification industry is anticipated to reach USD 1,949.3 million by 2035 end.
South Korea is expected to show a CAGR of 5.4% in the assessment period.
The key players operating in the global nucleic acid isolation and purification industry include Thermo Fisher Scientific, Inc., Promega Corporation, Agilent Technologies Inc., Illumina, Inc., Takara Bio, Inc., F. Hoffmann-La Roche AG, Danaher Corporation, QIAGEN, Bio-Rad Laboratories, Inc., Merck KgaA and New England Biolabs.
Explore In-vitro Diagnostics Devices Insights
Nucleic Acid Isolation and Purification Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
